Grantham, Mayo, Van Otterloo & Co (GMO)’s Dr. Reddy's Laboratories RDY Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$339K	Sell	23,401 -5,040	-18%	-$68K	﹤0.01%	596
2026 Q1	$394K	Sell	28,441 -315,792	-92%	-$4.4M	﹤0.01%	567
2025 Q4	$4.83M	Sell	344,233 -72,000	-17%	-$1.01M	0.01%	313
2025 Q3	$5.82M	Buy	416,233 +187,600	+82%	+$2.7M	0.02%	278
2025 Q2	$3.44M	Sell	228,633 -329,502	-59%	-$4.71M	0.01%	332
2025 Q1	$7.36M	Buy	558,135 +198,900	+55%	+$2.74M	0.02%	270
2024 Q4	$5.67M	Sell	359,235 -189,000	-34%	-$2.84M	0.02%	295
2024 Q3	$8.71M	Sell	548,235 -277,850	-34%	-$4.47M	0.03%	284
2024 Q2	$12.6M	Sell	826,085 -867,810	-51%	-$12.4M	0.04%	251
2024 Q1	$24.8M	Buy	1,693,895 +48,235	+3%	+$704K	0.09%	161
2023 Q4	$22.9M	Buy	1,645,660 +391,720	+31%	+$5.24M	0.1%	153
2023 Q3	$16.8M	Buy	1,253,940 +403,920	+48%	+$5.46M	0.08%	202
2023 Q2	$10.7M	Buy	850,020 +490,020	+136%	+$5.72M	0.05%	251
2023 Q1	$4.1M	Buy	360,000 +205,000	+132%	+$2.21M	0.02%	345
2022 Q4	$1.6M	Buy	155,000 +130,500	+533%	+$1.41M	0.01%	456
2022 Q3	$256K	Buy	+24,500	New	+$261K	﹤0.01%	651
2022 Q1	–	Sell	-27,000	Closed	-$353K	–	755
2021 Q4	$353K	Sell	27,000 -421,025	-94%	-$5.31M	﹤0.01%	634
2021 Q3	$5.84M	Sell	448,025 -342,515	-43%	-$4.56M	0.03%	310
2021 Q2	$11.6M	Sell	790,540 -617,000	-44%	-$8.63M	0.06%	233
2021 Q1	$17.3M	Sell	1,407,540 -645,000	-31%	-$8.28M	0.09%	170
2020 Q4	$29.3M	Sell	2,052,540 -164,500	-7%	-$2.22M	0.18%	77
2020 Q3	$30.8M	Sell	2,217,040 -34,000	-2%	-$405K	0.22%	65
2020 Q2	$23.9M	Sell	2,251,040 -743,000	-25%	-$7.56M	0.18%	76
2020 Q1	$24.1M	Buy	2,994,040 +315,500	+12%	+$2.63M	0.2%	76
2019 Q4	$21.7M	Buy	2,678,540 +336,500	+14%	+$2.66M	0.15%	111
2019 Q3	$17.7M	Sell	2,342,040 -533,000	-19%	-$3.96M	0.12%	119
2019 Q2	$21.5M	Buy	2,875,040 +86,500	+3%	+$680K	0.15%	107
2019 Q1	$22.6M	Buy	2,788,540 +98,500	+4%	+$748K	0.16%	96
2018 Q4	$20.3M	Buy	2,690,040 +766,500	+40%	+$5.39M	0.16%	92
2018 Q3	$13.3M	Buy	1,923,540 +1,730,040	+894%	+$11.6M	0.09%	133
2018 Q2	$1.25M	Sell	193,500 -6,000	-3%	-$37.8K	0.01%	354
2018 Q1	$1.3M	Buy	199,500 +142,000	+247%	+$995K	0.01%	356
2017 Q4	$432K	Buy	57,500 +21,500	+60%	+$155K	﹤0.01%	471
2017 Q3	$257K	Buy	36,000 +2,500	+7%	+$18K	﹤0.01%	496
2017 Q2	$282K	Buy	+33,500	New	+$272K	﹤0.01%	485
2017 Q1	–	Sell	-175,000	Closed	-$1.58M	–	632
2016 Q4	$1.58M	Sell	175,000 -76,000	-30%	-$707K	0.01%	334
2016 Q3	$2.33M	Sell	251,000 -150,000	-37%	-$1.43M	0.01%	317
2016 Q2	$4.11M	Sell	401,000 -32,500	-7%	-$298K	0.02%	312
2016 Q1	$3.92M	Buy	433,500 +395,000	+1,026%	+$3.53M	0.01%	320
2015 Q4	$356K	Buy	38,500 +12,000	+45%	+$131K	﹤0.01%	468
2015 Q3	$339K	Buy	+26,500	New	+$329K	﹤0.01%	505
2014 Q3	–	Sell	-26,500	Closed	-$229K	–	473
2014 Q2	$229K	Buy	+26,500	New	+$223K	﹤0.01%	464

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s RDY Position: Q2 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) reduced its Dr. Reddy's Laboratories (RDY) stake by 18% in Q2 2026, selling an estimated $68K and leaving 23,401 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #596.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in RDY in Q2 2014 and has held it in 42 quarters since. The position peaked at $30.8M in Q3 2020. 238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

Grantham, Mayo, Van Otterloo & Co (GMO) held 23,401 shares of Dr. Reddy's Laboratories worth $339K as of Q2 2026.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 5,040 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $68K.
Dr. Reddy's Laboratories made up ﹤0.01% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q2 2026, its #596 holding.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Dr. Reddy's Laboratories in Q2 2014 and has held it in 42 quarters since.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Dr. Reddy's Laboratories position peaked at $30.8M in Q3 2020.
238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2026, filed 13 Aug 2026.